Social media

As the Asia-Pacific (APAC) region continues to emerge as a key player in the biosimilar sector, it presents significant opportunity for market entry and expansion. In our latest blog on this region, we explore critical...

Your partner in cardiovascular device development. Our global team of experts—including interventional cardiologists, electrophysiologists, and statisticians—delivers integrated solutions for every stage of your device l...

Patient-centricity is at the core of everything we do. ICON partners with clients to design solutions that improve outcomes and deliver value. Join us at ISPOR Europe 2025 in Glasgow. https://ow.ly/pS6850Xfmcw #ISPOREu...

Patient-centricity is at the core of everything we do. ICON partners with clients to design solutions that improve outcomes and deliver value. Join us at ISPOR Europe 2025 in Glasgow. https://ow.ly/kJT550Xfmcx #ISPOREu...

From interventional cardiology to structural heart and cardiac imaging, ICON’s expertise spans the full spectrum of cardiovascular device development. Meet us at TCT 2025 to learn how we help bring life-saving innovation...

With decades of experience in interventional cardiology, structural heart, and cardiac imaging, we’re committed to advancing patient outcomes. Join us at TCT 2025 in San Francisco, Oct 25–28. https://ow.ly/YKFk50XeRv4 #...

Scaling cell therapy in APAC? ICON experts Tamie Joeckel & Meghan Morgan-Smith explore the infrastructure, regulatory, and supply chain hurdles—and how automation, partnerships, and harmonisation can unlock global potent...

With over 40 years of experience, ICON has supported hundreds of cardiovascular clinical studies across: - Interventional cardiology - Structural heart - Cardiac rhythm management - Cardiac imaging & diagnostics Meet us ...

Are you going to CPHI? If so come along to our VIP in-person event on Tuesday 28th October where our panel of industry experts will discuss the challenges around accelerating timelines and reducing costs in early clinica...

Are you going to CPHI? If so come along to our VIP in-person event on Tuesday 28th October where our panel of industry experts will discuss the challenges around accelerating timelines and reducing costs in early clinica...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...